Approaches in Barriers, Modifications, Route of Administrations, and Formulations of Therapeutic Agents for Brain Delivery

Kotha, Arun K.; Ghosh, Saikat; Komanduri, Neeraja; Wang, Rui; Bhowmick, Subhas; Chougule, Mahavir B.

doi:10.1007/978-981-13-3642-3_11

Cited by 1 publication

(1 citation statement)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The nasal delivery of peptides, such as insulin, was limited due to degradation and a short half-life. To address these concerns, researchers delved into the prodrug approach [ 178 ], which not only provides protection but also enhances lipophilicity [ 179 ]. The incorporation of absorption enhancers has also proven effective in augmenting nasal delivery and targeting [ 180 ].…”

Section: Transport Mechanisms Of Intranasal Routementioning

confidence: 99%

Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer’s Disease Management

Dighe,

Jog,

Momin

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Alzheimer’s disease, a progressive neurodegenerative condition, is characterized by a gradual decline in cognitive functions. Current treatment approaches primarily involve the administration of medications through oral, parenteral, and transdermal routes, aiming to improve cognitive function and alleviate symptoms. However, these treatments face limitations, such as low bioavailability and inadequate permeation. Alternative invasive methods, while explored, often entail discomfort and require specialized assistance. Therefore, the development of a non-invasive and efficient delivery system is crucial. Intranasal delivery has emerged as a potential solution, although it is constrained by the unique conditions of the nasal cavity. An innovative approach involves the use of nano-carriers based on nanotechnology for intranasal delivery. This strategy has the potential to overcome current limitations by providing enhanced bioavailability, improved permeation, effective traversal of the blood–brain barrier, extended retention within the body, and precise targeting of the brain. The comprehensive review focuses on the advancements in designing various types of nano-carriers, including polymeric nanoparticles, metal nanoparticles, lipid nanoparticles, liposomes, nanoemulsions, Quantum dots, and dendrimers. These nano-carriers are specifically tailored for the intranasal delivery of therapeutic agents aimed at combatting Alzheimer’s disease. In summary, the development and utilization of intranasal delivery systems based on nanotechnology show significant potential in surmounting the constraints of current Alzheimer’s disease treatment strategies. Nevertheless, it is essential to acknowledge regulatory as well as toxicity concerns associated with this route; meticulous consideration is required when engineering a carrier. This comprehensive review underscores the potential to revolutionize Alzheimer’s disease management and highlights the importance of addressing regulatory considerations for safe and effective implementations. Embracing this strategy could lead to substantial advancements in the field of Alzheimer’s disease treatment.

show abstract

Section: Transport Mechanisms Of Intranasal Routementioning

confidence: 99%